|Table of Contents|

The role of QRICH1 mediating NF-κB p65 in regulating Bcl-2 and Bax in arsenic-induced hepatocellular carcinoma cell apoptosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
235-241
Research Field:
Publishing date:

Info

Title:
The role of QRICH1 mediating NF-κB p65 in regulating Bcl-2 and Bax in arsenic-induced hepatocellular carcinoma cell apoptosis
Author(s):
WANG Junli; XIE Rujia; LIANG Cai; LI Jiayao; ZHANG Yingwan; YANG Qin; HAN Bing
Department of Pathophysiology,School of Basic Medicine,Guizhou Medical University Key Laboratory of Pathogenesis and Drug Research of Common Chronic Diseases of Guizhou Province,Guizhou Guiyang 550000,China.
Keywords:
arsenic; hepatoma cells; QRICH1; NF-κB p65; apoptosis
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2023.02.007
Abstract:
Objective:To explore the mechanism of QRICH1 regulating Bcl-2 and Bax by regulating the expression level of NF-κB p65 in the process of arsenic (AS)-induced apoptosis of liver cancer cells.Methods:Human hepatoma cells (HepG2 cells) were cultured in vitro,and lentiviral transfection was used to construct a HepG2 cell line that overexpressed/knocked down QRICH1 stably.They were divided into control group,arsenic addition group,arsenic+QRICH1 overexpression negative control group,arsenic+QRICH1 overexpression group,arsenic+QRICH1 knockdown negative control group and arsenic+QRICH1 knockdown group.In the logarithmic growth phase of cells,40 μmol/L sodium arsenite (NaAsO2) was added as the final concentration for 24 h.The control group was treated with the same volume of phosphate buffered saline (PBS) as NaAsO2.Cell proliferation was detected by cell counting (CCK-8).Cell apoptosis in each group was detected by flow cytometry.Western blot was used to detect the expression levels of QRICH1,NF-κB p65,Bcl-2 and Bax proteins in each group of cells.Results:The results of CCK-8 showed that compared with the control group,the proliferation rate of the arsenic treatment group was significantly lower (P＜0.05).Compared with the arsenic+QRICH1 overexpression negative control group,the proliferation rate of the arsenic+QRICH1 overexpression group was significantly increased (P＜0.05).Compared with the arsenic+QRICH1 knockdown negative control group,the cell proliferation rate in the arsenic+QRICH1 knockdown group was significantly decreased (P＜0.05),and the difference was statistically significant.The results of flow cytometry showed that compared with the control group,the proportion of total apoptosis in the arsenic treatment group was significantly increased (P＜0.05).Compared with the arsenic+QRICH1 overexpression negative control group,the total apoptosis rate of the arsenic+QRICH1 overexpression group was significantly decreased.Compared with the arsenic+QRICH1 knockdown negative control group,the proportion of total apoptosis rate in the arsenic+QRICH1 knockdown group was significantly increased (P＜0.05).Western blotting results showed that compared with the control group,the expression levels of QRICH1,NF-κB p65 and Bcl-2 proteins in the arsenic treatment group were lower,and the protein expression level of Bax was higher (P＜0.05).Compared with the arsenic+QRICH1 overexpression negative control group,the arsenic+QRICH1 overexpression group had higher protein expression levels of QRICH1,NF-κB p65 and Bcl-2,and lower protein expression levels of Bax(P＜0.05).Compared with the arsenic+QRICH1 knockdown negative control group,the arsenic+QRICH1 knockdown group had lower protein expression levels of QRICH1,NF-κB p65 and Bcl-2,and higher protein expression levels of Bax (P＜0.05),and the difference was statistically significant.Conclusion:In the process of arsenic-induced apoptosis of HepG2,QRICH1 affects the expression of Bcl-2 and Bax by regulating the expression of NF-κB p65.It is suggested that QRICH1 may be a potential target for promoting apoptosis of liver cancer cells.

References:

［1］CAI MJ,CUIY,FANG M,et al.Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma［J］.Gene,2019,702:66-74.
［2］SAYINER M,GOLABI P,YOUNOSSI ZM.Disease burden of hepatocellular carcinoma:a global perspective［J］.Dig Dis Sci,2019,64(4):910-917.
［3］王锦铭.基于全基因组Cas9筛选肝细胞癌对索拉非尼靶向治疗耐药的研究［D］.海口:海南医学院，2019. WANG JM.Screening of hepatocellular carcinoma resistance to sorafenib targeted therapy based on genome-wide Cas9 ［D］.Haikou:Hainan Medical College,2019.
［4］文柏清，康亚妮，毛建华.砷剂抗肿瘤作用机制的研究进展［J］.肿瘤研究与临床，2021，33(02):146-149. WEN BQ,KANG YN,MAO JH.Research progress on the mechanism of arsenic anti-tumor action［J］.Cancer Research and Clinical,2021,33(02):146-149.
［5］沈剑耀，任品芳，张志诚，等.三氧化二砷药物涂层支架治疗急性心肌梗死的疗效和安全性研究［J］.心电与循环，2019，38(06):494-497. SHEN JY,REN PF,ZHANG ZC,et al.Efficacy and safety of arsenic trioxide drug-coated stent in the treatment of acute myocardial infarction［J］.Electrocardiography and Circulation,2019,38(06):494-497.
［6］周珍，刘少平，周朗，等.黄芩素通过PI3K/AKT通路增强三氧化二砷对肝癌细胞的促凋亡作用［J］.现代肿瘤医学，2019，27(10):1661-1668. ZHOU Z,LIU SP,ZHOU L,et al.Baicalein enhances the pro-apoptotic effect of arsenic trioxide on liver cancer cells through PI3K/AKT pathway ［J］.Modern Oncology,2019,27(10):1661-1668.
［7］卞晓山，王作志，宋智兴.三氧化二砷经导管肝动脉化疗栓塞介入治疗中晚期原发性肝癌临床疗效及安全性观察［J］.临床和实验医学杂志，2021，20(07):705-708. BIAN XS,WANG ZZ,SONG ZX.Clinical efficacy and safety observation of arsenic trioxide transcatheter arterial chemoembolization in the treatment of middle-advanced primary liver cancer［J］.Journal of Clinical and Experimental Medicine,2021,20(07):705-708.
［8］LUI JC,JEE YH,LEE A,et al.QRICH1 mutations cause a chondrodysplasia with developmental delay［J］.Clin Genet,2019,95(1):160-164.
［9］丁涛，李腾越，李春宇,等.三氧化二砷对肝癌治疗的新进展［J］.吉林医药学院学报，2018，39(05):383-385. DING T,LI TY,LI CY,et al.New progress of arsenic trioxide in the treatment of liver cancer［J］.Journal of Jilin University of Medicine,2018,39(05):383-385.
［10］鲁会卿.三氧化二砷治疗急性早幼粒细胞白血病患者的临床效果［J］.临床医学研究与实践，2021，6(25):94-96. LU HQ.Clinical effect of arsenic trioxide in the treatment of patients with acute promyelocytic leukemia［J］.Clinical Medical Research and Practice,2021,6(25):94-96.
［11］奚曼,李慧波,苏胜,等.三氧化二砷治疗复发及难治性血液病的疗效及作用机制［J］.现代肿瘤医学，2019,27（15）：2795-2798. XI Man,LI Huibo,SU Sheng,et al.Efficacy and mechanism of arsenic trioxide in the treatment of relapsed and refractory hematological diseases［J］.Modern Oncology，2019,27（15）：2795-2798.
［12］WANG X,JIANG F,MU J,et al.Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491［J］.Toxicol Lett,2014,227(2):75-83.
［13］YE LJ,ZHOU XC,YIN XJ,et al.CARD9 downregulation suppresses the growth of oral squamous cell carcinoma by regulating NF-κB［J］.Oral Dis,2019,25(8):1886-1896.
［14］ZHONG X,CHEN B,YANG L,et al.Card9 as a critical regulator of tumor development［J］.Cancer Lett,2019,451:150-155.
［15］CHEN CW,WU MS,HUANG YJ,et al.The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC):the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling［J］.Cell Commun Signal,2015,10(6):1172-1186.
［16］YOU K,WANG L,CHOU CH,et al.QRICH1 dictates the outcome of ER stress through transcriptional control of proteostasis［J］.Science,2021,371(6524):45-71.
［17］ZHU H,SUN B,SHEN Q.TNF-α induces apoptosis of human nucleus pulposus cells via activating the TRIM14/NF-κB signalling pathway［J］.Artif Cells Nanomed Biotechnol,2019,47(1):3004-3012.
［18］ZHANG H,FU W.NDPP1 is a novel CARD domain containing protein which can inhibit apoptosis and suppress NF-kappaB activation［J］.Int J Oncol,2002,20(5):1035-1040.
［19］郏凯威，周烨，李振洋，等.CARD10通过活化NF-κB信号进而促进肝癌细胞凋亡抵抗［J］.中国肿瘤生物治疗杂志，2020，27(03):289-294. JIA KW,ZHOU Y,LI ZY,et al.CARD10 promotes apoptosis resistance of hepatocellular carcinoma cells by activating NF-κB signaling ［J］.Chinese Journal of Tumor Biotherapy,2020,27(03):289-294.

Memo

Memo:
贵州省科技合作计划项目（编号：黔科合平台人才［2018］5779-19)；贵州省科学技术基金（编号：黔科合基础-ZK［2021］一般364）
Last Update: 1900-01-01